Palvella Therapeutics Inc
PVLA37.140USD
+0.590+1.61%
交易中 （美東）報價延遲15分鐘
409.33M總市值
虧損本益比TTM
關於 Palvella Therapeutics Inc 公司
Palvella Therapeutics, Inc.（前身爲 Pieris Pharmaceuticals, Inc.）是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化新型療法，以治療患有嚴重、罕見遺傳性皮膚病的患者。該公司正在基於其專利的 QTORIN 平臺開發一系列候選產品，最初專注於嚴重、罕見的遺傳性皮膚病。其主要候選產品 QTORIN 3.9% 雷帕黴素無水凝膠（QTORIN 雷帕黴素）正在接受微囊性淋巴管畸形（微囊性 LM）的 III 期 SELVA 臨牀試驗和皮膚靜脈畸形的 II 期試驗。該公司還致力於開發其他嚴重的、功能性衰弱性皮膚病的治療方法，這些皮膚病是由哺乳動物雷帕黴素靶標 (mTOR) 通路過度激活引起的。
公司簡介
公司代碼PVLA
公司名稱Palvella Therapeutics Inc
上市日期Dec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
員工數量14
證券類型Ordinary Share
年結日Dec 18
公司地址125 Strafford Ave
城市WAYNE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編19087
電話14842531461
網址https://palvellatx.com/
公司代碼PVLA
上市日期Dec 18, 2014
CEOMr. Wesley H. (Wes) Kaupinen
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Jeffrey Martini, Ph.D.
Dr. Jeffrey Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月15日 週二
更新時間: 7月15日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Kaupinen (Wesley H.)
14.54%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Frazier Life Sciences Management, L.P.
6.24%
Samsara BioCapital, LLC
6.15%
Other
60.31%
持股股東
持股股東
佔比
Kaupinen (Wesley H.)
14.54%
Suvretta Capital Management, LLC
6.46%
BVF Partners L.P.
6.30%
Frazier Life Sciences Management, L.P.
6.24%
Samsara BioCapital, LLC
6.15%
Other
60.31%
股東類型
持股股東
佔比
Hedge Fund
23.10%
Individual Investor
17.80%
Private Equity
9.95%
Venture Capital
6.15%
Investment Advisor
6.11%
Other Insider Investor
5.06%
Investment Advisor/Hedge Fund
3.02%
Research Firm
0.46%
Other
28.36%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
110
7.92M
71.64%
+1.45M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
2023Q1
202
592.51K
63.79%
-198.90K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Kaupinen (Wesley H.)
1.61M
14.54%
--
--
Apr 14, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Mar 31, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
690.01K
6.24%
+36.12K
+5.52%
Mar 31, 2025
Samsara BioCapital, LLC
679.49K
6.15%
--
--
Mar 31, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
Adams Street Partners, LLC
409.67K
3.71%
--
--
Mar 31, 2025
Millennium Management LLC
269.84K
2.44%
+269.84K
--
Mar 31, 2025
Nantahala Capital Management, LLC
250.06K
2.26%
--
--
Mar 31, 2025
Jenkins (George M)
196.69K
1.78%
+4.99K
+2.60%
Apr 14, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.17%
iShares Micro-Cap ETF
0.03%
Global X Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 2000 ETF
0%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.17%
iShares Micro-Cap ETF
佔比0.03%
Global X Russell 2000 ETF
佔比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
公告日期
類型
比率
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
Apr 18, 2024
Merger
80<1
